Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 7

Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population

Authors Dalal A, Shah M, D’Souza AO, Chaudhari S, Crater G

Received 1 November 2011

Accepted for publication 24 November 2011

Published 18 January 2012 Volume 2012:7 Pages 11—19


Review by Single-blind

Peer reviewer comments 3

Anand A Dalal1, Manan Shah2, Anna O D'Souza2, Sham Chaudhari2, Glenn Crater1
1GlaxoSmithKline, Research Triangle Park, NC, USA; 2Xcenda LLC, Palm Harbor, FL, USA

Background: Chronic obstructive pulmonary disease (COPD) is frequently associated with comorbid depression and anxiety. Managing COPD symptoms and exacerbations through use of appropriate and adequate pharmacotherapy in this population may result in better COPD-related outcomes.
Methods: This retrospective, observational study used administrative claims of patients aged 40 years and older with COPD and comorbid depression/anxiety identified from January 1, 2004 through June 30, 2008. Patients were assigned to fluticasone propionate/salmeterol 250/50 mcg combination (FSC) or anticholinergics (AC) based on their first (index) prescription. The risks of COPD exacerbations and healthcare utilization and costs were compared between cohorts during 1 year of follow-up.
Results: The adjusted risk of a COPD-related exacerbation during the 1-year follow-up period was 30% higher in the AC cohort (n = 2923) relative to the FSC cohort (n = 1078) (odds ratio [OR]: 1.30, 95% confidence interval [CI]: 1.08–1.56) after controlling for baseline differences in covariates. The risks of COPD-related hospitalizations and emergency department visits were 56% and 65% higher, respectively, in the AC cohort compared with the FSC cohort. The average number of COPD-related hospitalizations during the follow-up period was 46% higher for the AC cohort compared with the FSC cohort (incidence rate ratio [IRR]: 1.46, 95% CI: 1.01–2.09, P = 0.041). The savings from lower COPD-related medical costs ($692 vs $1042, P < 0.050) kept the COPD-related total costs during the follow-up period comparable to those in the AC cohort ($1659 vs $1677, P > 0.050) although the pharmacy costs were higher in the FSC cohort.
Conclusions: FSC compared with AC was associated with more favorable COPD-related outcomes and lower COPD-related utilization and medical costs among patients with COPD and comorbid anxiety/depression.

Keywords: COPD, fluticasone propionate/salmeterol, anticholinergics, depression, comorbidity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States

Diette GB, Dalal AA, D’Souza AO, Lunacsek OE, Nagar SP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:415-422

Published Date: 24 February 2015

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Direct costs of chronic obstructive pulmonary disease among managed care patients

Anand A Dalal, Laura Christensen, Fang Liu, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:341-349

Published Date: 30 September 2010

Readers of this article also read:

COPD exacerbation frequency and its association with health care resource utilization and costs

Dhamane AD, Moretz C, Zhou Y, Burslem K, Saverno K, Jain G, Renda A, Kaila S

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2609-2618

Published Date: 3 December 2015

Effect of surface roughness on osteogenesis in vitro and osseointegration in vivo of carbon fiber-reinforced polyetheretherketone–nanohydroxyapatite composite

Deng Y, Liu X, Xu A, Wang L, Luo Z, Zheng Y, Deng F, Wei J, Tang Z, Wei S

International Journal of Nanomedicine 2015, 10:1425-1447

Published Date: 17 February 2015

Biocomposite nanofibrous strategies for the controlled release of biomolecules for skin tissue regeneration

Gandhimathi C, Venugopal JR, Bhaarathy V, Ramakrishna S, Kumar SD

International Journal of Nanomedicine 2014, 9:4709-4722

Published Date: 8 October 2014

The mediating role of cytokine IL-6 on the relationship of FEV1 upon 6-minute walk distance in chronic obstructive pulmonary disease

Baldi S, Jose PE, Bruschi C, Pinna GD, Maestri R, Rezzani A, Bellinzona E, Fracchia C, Dacosto E, Crotti P, Montemartini S

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1091-1099

Published Date: 7 October 2014

Probing the mechanical properties of TNF-α stimulated endothelial cell with atomic force microscopy [Corrigendum]

Lee SY, Zaske AM, Novellino T, Danila D, Ferrari M, Conyers J, Decuzzi P

International Journal of Nanomedicine 2014, 9:2567-2568

Published Date: 23 May 2014